Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in lung cancer
- Trial result
Lung cancer
Larotrectinib (TRK inhibitor) delivers 69% ORR and ~19-mo PFS in NTRK fusion lung cancer
Larotrectinib is a first-in-class, highly selective, CNS-active TRK (NTRK1/2/3) tyrosine kinase inhibitor evaluated in an updated pooled subset from two clinical trials (NCT02122913; Phase I/II NAVIGATE, NCT02576431)…
NCT02122913 - New trial
Lung cancer
Phase 2 HEARTS trial: MRgART, MRI-guided adaptive radiotherapy targeting cardiac sparing in thoracic cancers.
This study compares an investigational MRgART that uses real-time imaging adjustments to spare the heart with standard LINAC radiation therapy employing stereotactic external beam delivery. Eligible patients include…
NCT07132918 Exploratory - Trial result
Lung cancer
ctDNA Tumor Fraction Clearance Predicts Longer rwPFS/OS in NSCLC & SCLC
A tissue-agnostic ctDNA tumor-fraction (TF) assay measured 6–15 weeks after therapy start (prospective clinico-genomic registry; NCT04180176) associated undetectable TF with longer real-world outcomes: NSCLC mPFS…
NCT04180176 - New trial
Lung cancer
Phase 1 Expansion: XeMRI-guided SBRT using xenon contrast for lung function imaging.
This study evaluates whether functionally adapted SBRT, guided by xenon-enhanced MRI, can better preserve lung function in lung cancer patients. Participants receive either standard SBRT with conventional imaging or…
NCT06925295 Exploratory - New trial
Lung cancer
Phase 3 Trial of N-803 + Tislelizumab + Docetaxel in NSCLC with EGFR Mutations
ImmunityBio is evaluating an experimental combination of N-803—a two human IL-15 variant fusion protein that enhances immunostimulation—plus tislelizumab (a PD-1 inhibitor) and docetaxel versus docetaxel monotherapy…
NCT06745908 - New trial
Lung cancer
Phase Ib/II Trial of BNT324 (B7-H3 ADC) + BNT327 (PD-L1/VEGF Bispecific) in Advanced Lung Cancer
BioNTech SE is evaluating the combination of BNT324—a B7-H3 antibody-drug conjugate delivering an undisclosed toxin—with BNT327, a VEGFA directed antibody that also targets PD-L1 and VEGF, across multiple cohorts in…
NCT06892548 - New trial
Lung cancer
Phase 1b Study of Tarlatamab (DLL3/CD3) & YL201 (B7-H3 ADC) ± anti-PD-L1 in Extensive Stage SCLC
Amgen is evaluating the safety, tolerability, and efficacy of combining tarlatamab—a bispecific mAb targeting DLL3 and CD3—with YL201, a B7-H3 directed ADC, with or without PD-L1 inhibitors in extensive stage SCLC…
NCT06898957
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.